SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Keith Feral who wrote (318)10/1/2007 6:08:10 PM
From: Keith FeralRead Replies (1) of 418
 
Here are a few links to explain infusional vs bolus administrations. I think that more frequent treatment in a bolus administration would be preferable if the toxicity was not going to become an issue. With Cofactor showing great safety results in both trials, even if the phase 2 b was not statistically better than infusional 5FU and leucovorin, I get the sense why bolus Cofactor worked so much better than infusional Cofactor. The more frequently the body can be dosed with 5FU, the more it shuts down the TS pathway in the cancer cells. I would prefer to get more frequent Cofactor and 5FU treatments to work agains the cancer cells in a daily regimen.

The whole reason that bolus leucovorin in being challenged by infusional leucovorin is a function of safety. Bolus Cofactor does not seem to have any significant safety issues, so that people can continue to receive the cytotoxic drugs like 5FU on a daily regimen.

cancerbackup.org.uk

cancer.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News